
MannKind (MNKD) Stock Forecast & Price Target
MannKind (MNKD) Analyst Ratings
Bulls say
MannKind is a biopharmaceutical company with a positive outlook due to the potential growth of its royalty and collaboration revenue streams, including the pursuit of Tyvaso DPI for interstitial pulmonary fibrosis (IPF). Additionally, the company's MNKD-201 nintedanib DPI program in IPF and MNKD-1501 ralinepag DPI program for pulmonary arterial hypertension (PAH) provide additional upside potential. Despite reporting lighter-than-expected earnings, the company has a strong balance sheet and multiple upcoming catalysts, making it a favorable investment opportunity with a price target of $10-11 based on a discounted cash flow model. However, risks include commercial execution, clinical trials, and regulatory risks, as well as the possibility of a partner controlling commercialization of key products.
Bears say
MannKind is a biopharmaceutical company with three commercially available products, but our analysis shows potential challenges for sustained growth. Though the company has a promising catalyst in the upcoming FDA decision on the 7/26/26 FUROSCIX ReadyFlow autoinjector, the shift to this format may not be as smooth as expected, with potential cost and training hurdles. This, as well as the seasonal and transitional nature of FUROSCIX sales, indicate potential difficulties in driving long-term revenue growth.
This aggregate rating is based on analysts' research of MannKind and is not a guaranteed prediction by Public.com or investment advice.
MannKind (MNKD) Analyst Forecast & Price Prediction
Start investing in MannKind (MNKD)
Order type
Buy in
Order amount
Est. shares
0 shares